Orally Inhaled Dihydroergotamine: A Review

The International Classification of Headache Disorders, 3rd edition (beta version)

(2013)   CEPHALALGIA

Assessment of the Consistency of Absorption of Dihydroergotamine Following Oral Inhalation: Pooled Results from Four Clinical Studies

(2012) Donald J. Kellerman et al.   Journal of Aerosol Medicine and Pulmonary Drug Delivery

Lack of drug interaction between the migraine drug MAP0004 (orally inhaled dihydroergotamine) and a CYP3A4 inhibitor in humans

(2011) D Kellerman et al.   CEPHALALGIA

Efficacy and Safety of MAP0004, Orally Inhaled DHE in Treating Migraines With and Without Allodynia

(2011) Stewart J. Tepper et al.   HEADACHE

MAP0004, Orally Inhaled DHE: A Randomized, Controlled Study in the Acute Treatment of Migraine

(2011) Sheena K. Aurora et al.   HEADACHE

MAP0004, Orally Inhaled Dihydroergotamine for Acute Treatment of Migraine: Efficacy of Early and Late Treatments

(2011) Stewart J. Tepper et al.   MAYO CLINIC PROCEEDINGS

Reduced Adverse Event Profile of Orally Inhaled DHE (MAP0004) vs IV DHE: Potential Mechanism

(2009) Robert O. Cook et al.   HEADACHE

Randomized, double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of MAP0004 (orally-inhaled DHE) in adult asthmatics

(2008) Stephen B. Shrewsbury et al.   CURRENT MEDICAL RESEARCH AND OPINION

Perimenstrual migraines: Are they different from migraines in general?

(2008) Stewart J. Tepper   Current Pain and Headache Reports

Breath-synchronized plume-control inhaler for pulmonary delivery of fluticasone propionate

(2008) Stephen B. Shrewsbury et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS